Key result
SAHA significantly inhibited TGF-β-induced lung fibroblast proliferation, migration, and fibrosis-related gene expression by epigenetically increasing p66Shc expression and mitochondrial ROS.
Why the study?
To investigate the effects of suberoylanilide hydroxamic acid (SAHA) on lung fibroblast activation and examine the role of p66Shc in this process.
Does SAHA inhibit lung fibroblast activation in an in vitro pulmonary fibrosis model?
Does SAHA inhibit lung fibroblast activation in an in vitro pulmonary fibrosis model?
SAHA alleviates lung fibroblast activation and migration by epigenetically upregulating p66Shc expression and increasing mitochondrial ROS generation.
SAHA may target fibroblast activation via p66Shc in fibrosis models; leaves open clinical translation pending human studies.
Objectives: To investigate the effects of suberoylanilide hydroxamic acid (SAHA) on lung fibroblast activation and to examine the role of p66Shc in this process. Methods: An in vitro pulmonary fibrosis model was established using transforming growth factor-β (TGF-β)-induced MRC-5 lung fibroblasts. The proliferation and migration capacities of MRC-5 cells, along with the expression of fibrosis-related genes, were assessed following treatment with SAHA and/or silence of p66Shc. Results: In TGF-β-induced MRC-5 lung fibroblasts, SAHA treatment significantly inhibited cell proliferation and migration, as well as the expression of fibrosis-related genes, including collagen I and α-smooth muscle actin (SMA). Western blot and immunofluorescence assays revealed that SAHA increased p66Shc expression in both whole cells and mitochondria. Additionally, mito-SOX assay confirmed that SAHA treatment led to a marked accumulation of mitochondrial reactive oxygen species (ROS). However, silencing of p66Shc significantly reversed the aforementioned effects of SAHA on MRC-5 cells. Furthermore, chromatin immunoprecipitation (ChIP) assays demonstrated that SAHA enhanced active histone markers, H3K9Ac and H3K4Me3, in the p66Shc gene region. Conclusions: SAHA alleviates lung fibroblast activation and migration by increasing p66Shc expression and mitochondrial ROS generation through epigenetic modifications of histone 3.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2024) studied Pulmonary fibrosis (in vitro model). Suberoylanilide hydroxamic acid (SAHA) vs. Control / silencing of p66Shc was evaluated on Cell proliferation, migration, and expression of fibrosis-related genes. SAHA significantly inhibited TGF-β-induced lung fibroblast proliferation, migration, and fibrosis-related gene expression by epigenetically increasing p66Shc expression and mitochondrial ROS.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: